Back to search results

MAGESTIC Trial: Testing a Blood Marker for Testicular Cancer

This study, called MAGESTIC, is looking at how well a blood test can find active testicular cancer (Malignant Testicular Germ Cell Tumor). It specifically checks for a biomarker (a biological sign in the body) called miRNA-371. The study aims to see if this blood test can accurately predict if cancer is present before surgery. You might be able to join if you are an adult man (18 years or older) who has had surgery to remove a primary testicular tumor and have certain stages of testicular cancer (Clinical Stage I or IIA/B seminoma or non-seminoma). The study will follow participants for up to 5 years. The current recruitment status is unclear, and the study plans to enroll 418 participants.

Study design
This is an observational study, meaning researchers will watch and collect information without giving specific treatments. It plans to enroll 418 adult men.
What's involved
You would provide blood samples during screening and throughout the study. Your medical records may also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
You would be followed until year 5, or through study completion, up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06060873

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Recruiting
Not specifiedAges 18+Observational
University of Southern California
~418 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Clinical Stage I DiseaseClinical Stage I with relapse, CSII Disease

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accuracy of miRNA-371 to predict pre-operatively the presence of active germ cell malignancy
Measured over Through study completion, up to 5 years

Conditions

Malignant Testicular Germ Cell Tumor

Explore related trials

Testicular Germ Cell TumorAlpha-Fetoproteinβ-HCG

Where it's being run

7 sites across 5 states
California3
Alabama1
Georgia1
New Jersey1
Ontario1

Study leadership

  • Siamak Daneshmand, MD · PRINCIPAL_INVESTIGATOR · University of Southern California

Who to contact

Ileana Aldana
[email protected]
323-865-0702
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Primary tumor excised by radical inguinal orchiectomy and pathology consistent with GCT (seminoma or NSGCT)
Clinical stage of patient is either:
Stage I pure seminoma OR stage I pure seminoma with isolated retroperitoneal relapse or Stage IIA/B pure seminoma
Stage I NSGCT OR stage I NSGCT with isolated retroperitoneal relapse or Stage IIA/B NSGCT
For subjects with retroperitoneal lymphadenopathy: no lymph node \>3 cm in greatest dimension with no more than 2 nodes enlarged
Axial abdominal/pelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 3 months of enrollment if stage I patient
Axial abdominal/pelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 8 weeks of enrollment if stage II patient
miRNA-371 can be drawn and sent for analysis at time of consent
Enrollment within 1 year after orchiectomy for stage I patients
Enrollment at any timepoint after orchiectomy for stage II patients
Retroperitoneal lymphadenopathy must be within an RPLND template
Biopsy of lymph node is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with GCT
Serum Alpha Feto Protein (AFP) \<50 ng/ml, β-Human Chorionic Gonadotropin (β-HCG) 25 mIU/ml within 42 days (6 weeks) of enrollment
Age ≥ 18 years
Ability to understand and the willingness to sign a written informed consent

Exclusion

Second primary malignancy
Patients receiving any other investigational agent (s)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

What this trial measures

  • Accuracy of miRNA-371 to predict pre-operatively the presence of active germ cell malignancyThrough study completion, up to 5 years

    The positive predictive value of pre-operatively elevated miRNA-371 levels in predicting active GCT will be determined by pathologic review of RPLND specimens.